Answers are grounded in this paper and cite their sources.
In a climate of spending review and pharmaeconomics any prescriptio should be made according to recognized indications, also to limit exposion of fragile patients to possible secondary effects and complication. In this editorial we comment on the case of PPIs in patients with cirrhosis or with polypathology.
No takes yet. Share an insight, caveat, or question.
Antonio Picardi (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: